Howe & Rusling Inc. Has $11.27 Million Holdings in Johnson & Johnson (JNJ)
Howe & Rusling Inc. raised its holdings in Johnson & Johnson (NYSE:JNJ) by 2.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 85,201 shares of the company’s stock after purchasing an additional 2,146 shares during the period. Johnson & Johnson comprises approximately 2.3% of Howe & Rusling Inc.’s holdings, making the stock its 8th largest holding. Howe & Rusling Inc.’s holdings in Johnson & Johnson were worth $11,271,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in JNJ. Capital Asset Advisory Services LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $219,000. First National Bank of Omaha increased its holdings in shares of Johnson & Johnson by 8.0% in the 1st quarter. First National Bank of Omaha now owns 52,648 shares of the company’s stock valued at $6,558,000 after acquiring an additional 3,919 shares during the last quarter. Stillwater Capital Advisors LLC increased its holdings in shares of Johnson & Johnson by 46.2% in the 1st quarter. Stillwater Capital Advisors LLC now owns 87,867 shares of the company’s stock valued at $10,944,000 after acquiring an additional 27,785 shares during the last quarter. TNB Financial bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $3,438,000. Finally, Horan Capital Management increased its holdings in shares of Johnson & Johnson by 5.8% in the 1st quarter. Horan Capital Management now owns 66,552 shares of the company’s stock valued at $8,289,000 after acquiring an additional 3,633 shares during the last quarter. 65.90% of the stock is currently owned by institutional investors.
Shares of Johnson & Johnson (NYSE JNJ) traded up 0.14% on Thursday, reaching $136.84. The company’s stock had a trading volume of 2,796,170 shares. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.52. The stock has a market capitalization of $367.28 billion, a price-to-earnings ratio of 23.15 and a beta of 0.78. The stock has a 50-day moving average of $132.32 and a 200 day moving average of $130.07.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. During the same period last year, the firm posted $1.74 EPS. The business’s revenue was up 1.9% on a year-over-year basis. On average, analysts expect that Johnson & Johnson will post $7.18 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th were issued a dividend of $0.84 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a yield of 2.46%. Johnson & Johnson’s dividend payout ratio is 56.76%.
COPYRIGHT VIOLATION WARNING: “Howe & Rusling Inc. Has $11.27 Million Holdings in Johnson & Johnson (JNJ)” was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://theolympiareport.com/2017/10/12/howe-rusling-inc-has-11-27-million-holdings-in-johnson-johnson-jnj.html.
A number of brokerages have recently weighed in on JNJ. Jefferies Group LLC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price target for the company from $145.00 to $157.00 in a report on Wednesday. Wells Fargo & Company upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $140.00 to $149.00 in a report on Monday. Cowen and Company set a $147.00 price target on Johnson & Johnson and gave the company a “buy” rating in a report on Friday, October 6th. Zacks Investment Research upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th. Finally, Piper Jaffray Companies reiterated a “hold” rating and issued a $120.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 4th. Five research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $136.02.
In related news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the sale, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.